{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:33:38Z","timestamp":1780432418415,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jhepr.2021.100417","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:19:17Z","timestamp":1639621157000},"page":"100417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-2767","authenticated-orcid":false,"given":"Felix","family":"Thol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-5152","authenticated-orcid":false,"given":"Simon Johannes","family":"Gairing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Czauderna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-7965","authenticated-orcid":false,"given":"Thomas","family":"Thomaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gamst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-1623","authenticated-orcid":false,"given":"Yvonne","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Vollmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6090-2530","authenticated-orcid":false,"given":"Fabian","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-4792","authenticated-orcid":false,"given":"Roman","family":"Kloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0621","authenticated-orcid":false,"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Uwe","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-8891","authenticated-orcid":false,"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100417_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100417_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100417_bib3","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/CMAR.S157092","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges","volume":"11","author":"Tariq","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2021.100417_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.14100","article-title":"Medical treatment for cholangiocarcinoma","volume":"39","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2021.100417_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100417_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","article-title":"Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis","volume":"26","author":"Lendvai","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jhepr.2021.100417_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2021.100417_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474124.2021.1890031","article-title":"Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100417_bib9","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","article-title":"Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin","volume":"57","author":"Dierks","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100417_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-020-07004-y","article-title":"A\u00a0retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer","volume":"20","author":"Ulusakarya","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-020-01045-7","article-title":"Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study","author":"Ye","year":"2021","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.jhepr.2021.100417_bib19","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","author":"Phelip","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","article-title":"Current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"123","author":"Marin","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS597","article-title":"FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M\/A)","volume":"38","author":"Javle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4155","article-title":"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF trial","volume":"37","author":"Javle","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600","volume":"38","author":"Borad","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib26","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib28","first-page":"100335","article-title":"First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: \"and yet it moves!\"","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jhepr.2021.100417_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andre","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib30","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.29471","article-title":"Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Enterologues Oncologues","volume":"121","author":"Brieau","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib32","first-page":"44","article-title":"Second-line chemotherapy prolongs survival in real world patients with advanced biliary tract and gallbladder cancers: a multicenter retrospective population-based cohort study","author":"Zaidi","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12885-018-5223-7","article-title":"Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program","volume":"19","author":"Moehler","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib34","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib35","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.bjc.6605377","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A\u00a0phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.dld.2018.11.018","article-title":"Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II\/III study","volume":"51","author":"Phelip","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100417_bib41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41416-019-0698-9","article-title":"Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial","volume":"122","author":"Belkouz","year":"2020","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2021.100417_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.31278","article-title":"Molecular targets in cholangiocarcinoma","volume":"73","author":"O'Rourke","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100417_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS545","article-title":"ClarIDHy: a phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation","volume":"36","author":"Abou-Alfa","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies","volume":"37","author":"Bang","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT283","article-title":"Abstract CT283: KEYNOTE-966: a randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma","volume":"80","author":"Finn","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100417_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz247.157","article-title":"A\u00a0phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1","volume":"30","author":"Oh","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib48","first-page":"428","article-title":"A\u00a0population based analysis of prognostic factors in advanced biliary tract cancer","volume":"5","author":"Peixoto","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib49","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.24472","article-title":"Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy","volume":"115","author":"Park","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib51","article-title":"Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients","volume":"13","author":"Kang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2021.100417_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-010-1360-7","article-title":"Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy","volume":"67","author":"Sasaki","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhepr.2021.100417_bib53","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ejso.2019.04.019","article-title":"The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma","volume":"45","author":"Lurje","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib54","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib55","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.05.014","article-title":"Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer","volume":"73","author":"McNamara","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100417_bib56","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ejca.2015.04.011","article-title":"Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer","volume":"51","author":"Grunnet","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2021.100417_bib57","first-page":"6180613","article-title":"Risk stratification in advanced biliary tract cancer: validation of the A.L.A.N. Score","volume":"2020","author":"Muller","year":"2020","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.jhepr.2021.100417_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12032-014-0287-y","article-title":"Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status","volume":"31","author":"Moriwaki","year":"2014","journal-title":"Med Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:06Z","timestamp":1762900026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2589555921001932"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100417","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100417"}}